The results among all cancers indicated that high expression of HHLA2 in human tumor tissue was associated with shorter RFS compared to low expression of HHLA2 (HR = 1.95, 95% CI: 1.38–2.77) as shown in Figure 5B. The meta-analysis of the HR rate for DFS rate showed that the patients with high HHLA2 expression had worse DFS than those with low expression (common effect model, HR = 1.45, 95% CI: 1.01–2.09) (Figure 5D). The gene discussed is HHLA2; the disease is cancer.